Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Increasing Rate of Hospital Admissions in Patients With Amyloidosis (from the National Inpatient Sample).

Sperry BW, Saeed IM, Raza S, Kennedy KF, Hanna M, Spertus JA.

Am J Cardiol. 2019 Dec 1;124(11):1765-1769. doi: 10.1016/j.amjcard.2019.08.045. Epub 2019 Sep 10.

PMID:
31607373
2.

Regional Variability in Longitudinal Strain Across Vendors in Patients With Cardiomyopathy Due to Increased Left Ventricular Wall Thickness.

Sperry BW, Sato K, Phelan D, Grimm R, Desai MY, Hanna M, Jaber WA, Popović ZB.

Circ Cardiovasc Imaging. 2019 Aug;12(8):e008973. doi: 10.1161/CIRCIMAGING.119.008973. Epub 2019 Aug 15.

PMID:
31412719
3.

Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis.

Donnelly JP, Hanna M, Sperry BW, Seitz WH Jr.

J Hand Surg Am. 2019 Oct;44(10):868-876. doi: 10.1016/j.jhsa.2019.06.016. Epub 2019 Aug 7. Review.

PMID:
31400950
4.

Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience.

Ikram A, Donnelly JP, Sperry BW, Samaras C, Valent J, Hanna M.

Amyloid. 2018 Sep;25(3):197-202. doi: 10.1080/13506129.2018.1519507. Epub 2018 Nov 2.

PMID:
30388377
5.

Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release.

Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M.

J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050. doi: 10.1016/j.jacc.2018.07.092.

6.

Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis.

Sperry BW, Gonzalez MH, Brunken R, Cerqueira MD, Hanna M, Jaber WA.

J Nucl Cardiol. 2019 Oct;26(5):1630-1637. doi: 10.1007/s12350-017-1166-7. Epub 2018 Jan 17.

PMID:
29344917
7.

Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality.

Sperry BW, Vranian MN, Tower-Rader A, Hachamovitch R, Hanna M, Brunken R, Phelan D, Cerqueira MD, Jaber WA.

JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):234-242. doi: 10.1016/j.jcmg.2017.06.020. Epub 2017 Oct 5.

8.

Editorial commentary: Cardiac amyloidosis-Reversing the mindset and the cardiomyopathy.

Sperry BW.

Trends Cardiovasc Med. 2018 Jan;28(1):22-23. doi: 10.1016/j.tcm.2017.07.005. Epub 2017 Jul 18. No abstract available.

PMID:
28754231
9.

Complex p.T88N/W130R mutation in the lysozyme gene leading to hereditary lysozyme amyloidosis with biopsy-proven cardiac involvement.

Sperry BW, Dispenzieri A, Ikram A, Grogan M, Theis JD, Leung N, Highsmith WE, Maleszewski JJ, Hanna M.

Amyloid. 2017 Mar;24(1):60-61. doi: 10.1080/13506129.2016.1269738. Epub 2017 Mar 22. No abstract available.

PMID:
28330375
10.

Amyloid heart disease: genetics translated into disease-modifying therapy.

Sperry BW, Tang WHW.

Heart. 2017 Jun;103(11):812-817. doi: 10.1136/heartjnl-2016-309914. Epub 2017 Mar 2. Review.

PMID:
28255101
11.

Prognosis Using Planar Imaging in Cardiac Amyloidosis.

Sperry BW, Brunken R, Jaber WA.

JAMA Cardiol. 2017 Jun 1;2(6):704. doi: 10.1001/jamacardio.2016.5885. No abstract available.

PMID:
28241246
12.

Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes.

Vranian MN, Sperry BW, Hanna M, Hachamovitch R, Ikram A, Brunken RC, Jaber WA.

J Nucl Cardiol. 2018 Aug;25(4):1247-1256. doi: 10.1007/s12350-016-0768-9. Epub 2017 Jan 3.

PMID:
28050864
13.

Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure.

Sperry BW, Ikram A, Hachamovitch R, Valent J, Vranian MN, Phelan D, Hanna M.

J Am Coll Cardiol. 2016 Jun 28;67(25):2941-8. doi: 10.1016/j.jacc.2016.03.593.

14.

Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings.

Sperry BW, Vranian MN, Hachamovitch R, Joshi H, McCarthy M, Ikram A, Hanna M.

Int J Cardiol. 2016 Jul 1;214:477-81. doi: 10.1016/j.ijcard.2016.04.030. Epub 2016 Apr 8.

PMID:
27093686
15.

Recognizing Transthyretin Cardiac Amyloidosis in Patients With Aortic Stenosis: Impact on Prognosis.

Sperry BW, Jones BM, Vranian MN, Hanna M, Jaber WA.

JACC Cardiovasc Imaging. 2016 Jul;9(7):904-906. doi: 10.1016/j.jcmg.2015.10.023. Epub 2016 Apr 13. No abstract available.

16.

Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.

Sperry BW, Vranian MN, Hachamovitch R, Joshi H, Ikram A, Phelan D, Hanna M.

J Am Heart Assoc. 2016 Mar 24;5(3):e002877. doi: 10.1161/JAHA.115.002877.

17.

Prognostic implication of relative regional strain ratio in cardiac amyloidosis.

Senapati A, Sperry BW, Grodin JL, Kusunose K, Thavendiranathan P, Jaber W, Collier P, Hanna M, Popovic ZB, Phelan D.

Heart. 2016 May 15;102(10):748-54. doi: 10.1136/heartjnl-2015-308657. Epub 2016 Feb 1. Erratum in: Heart. 2016 Sep 1;102(17):1419.

PMID:
26830665
18.

Emerging Advances in the Management of Cardiac Amyloidosis.

Vranian MN, Sperry BW, Valent J, Hanna M.

Curr Cardiol Rep. 2015 Nov;17(11):100. doi: 10.1007/s11886-015-0653-1. Review.

PMID:
26374453

Supplemental Content

Loading ...
Support Center